TS
KLRA

Thomas Steyer’s Kailera Therapeutics KLRA Stock Holding History

Thomas Steyer’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.2M Buy
+1,100,000
New +$24.2M 0.11% 50

Other funds holding KLRA

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Thomas Steyer's KLRA Position: Q2 2026 in Review

Thomas Steyer opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 1,100,000 shares worth $24.2M. The stake represents 0.11% of the portfolio and ranks #50 among its holdings.

98 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

  • Thomas Steyer held 1,100,000 shares of Kailera Therapeutics worth $24.2M as of Q2 2026.
  • Kailera Therapeutics was a new Thomas Steyer position in Q2 2026.
  • Kailera Therapeutics made up 0.11% of Thomas Steyer's portfolio in Q2 2026, its #50 holding.
  • 98 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.